Oragenics Awarded a $250,000 Grant From the National Institute of General Medical Sciences (NIGMS) for the Continued Research and Development of Lantibiotics
UF startup and UF Innovate | Sid Martin Biotech graduate Oragenics, Inc., announced that it was awarded a small business innovation research grant in the amount of $250,000 (Computer-aided Design for Improved Lantibiotics R41GM136034) for the company’s continued research and development of lantibiotics, including its collaborative program with the Biomolecular Sciences Institute at Florida International University (FIU).
AGTC: The New Leader in Ocular Gene Therapy With Sue Washer
Sue Washer, president and CEO of Applied Genetic Technologies Corporation (AGTC), discusses ocular gene therapy with the Eye Care Insider podcast host Joshua Mali, MD.
Oragenics Initiates COVID-19 Challenge Study Evaluating Multiple Formulations of Its SARS-CoV-2 Vaccine Candidate
UF startup and UF Innovate | Sid Martin Biotech graduate Oragenics, Inc. announced the initiation of a study to evaluate the immunogenicity and viral load reduction impact of its SARS-CoV-2 vaccine candidate in a hamster challenge study.
AGTC Is Excited To Announce Seasoned Healthcare Financial and Operations Executive Jonathan I. Lieber As Their New Chief Financial Officer
UF startup and UF Innovate | Sid Martin Biotech graduate Applied Genetic Technologies Corporation (AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare retinal diseases, announced Jonathan I. Lieber as their new Chief Financial Officer.
TearClear Files Investigational New Drug (IND) Application To Begin Its Clinical Trial for TC-002 Latanoprost Ophthalmic Solution, 0.005%
UF startup and UF Innovate | Sid Martin Biotech company TearClear, a late clinical-stage ophthalmic pharmaceutical company, has filed an Investigational New Drug (IND) application to conduct a registrational study for its lead glaucoma candidate, TC-002 latanoprost ophthalmic solution, 0.005%.
Can Handheld DNA Testing Technology Stand Up to Seafood Fraud?
When LeeAnn Applewhite started running DNA analysis on commercial seafood samples in 2015, 75 percent of them – species ranging from grouper and snapper to catfish and shrimp – were mislabeled. “We were testing thousands of samples, and some of it was unintentional mislabeling; it was a bycatch species with [species like] grouper or snapper but the whole load was not erroneously labeled,” said Applewhite, co-founder and president of UF Innovate | Sid Martin Biotech graduate Applied Food Technologies.
Axogen RECON(SM) Clinical Study Completes Subject Follow-Up
UF startup and UF Innovate | Sid Martin Biotech graduate Axogen, a global leader in developing and marketing innovative surgical solutions for damage or discontinuity to peripheral nerves, announced that the RECON Clinical Study supporting its Biologics License Application (BLA) for Avance Nerve Graft has completed follow-up of study subjects.
Oragenics’ SARS-CoV-2 Spike Protein Produces Neutralizing Antibodies in Mice With Intramuscular and Intranasal Adjuvants
UF startup and UF Innovate | Sid Martin Biotech graduate Oragenics, Inc., a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis, announces that the stabilized pre-fusion spike protein trimer produced by its Canadian collaborator and licensed by the company from the National Institutes of Health (NIH) generates neutralizing antibodies in mice after immunization against SARS-CoV-2, when administered with several novel intramuscular (IM) and intranasal (IN) adjuvants.
CFO of Life Science Startup Axogen Shares How Firm Navigated Pandemic’s Health Care Disruptions
UF startup and UF Innovate | Sid Martin Biotech graduate Axogen, a life science company that is developing products for nerve repair, is ramping up hiring for scientists and engineers after navigating through the negative disruptions from the Covid-19 pandemic.
Two-Year Backlog in Biologicals Manufacturing Hinders Medical R&D, Development of New Therapies for COVID-19
One area where COVID-19 has had a substantial impact is the development and manufacturing of medicines, medical devices, and pharmaceutical products. The CDMO industry is showing enormous growth and is projected to become a $315 billion industry by 2026. However, the demand for products skyrocketed so quickly that supply has not been able to keep pace. According to Dr. Ian White, president and CSO of Neobiosis, a UF Innovate | Sid Martin Biotech resident company that focuses on the science of regenerative medicine, demand has caused a two-year backlog of desperately needed cellular and acellular products for use in research and clinical trials directed at treating the COVID-19 virus and its complications (AKA Post-COVID Syndrome).
